When cancer spreads to the delicate membranes surrounding the brain and spinal cord, it creates a serious complication known as leptomeningeal metastases. Understanding the available treatments and emerging therapies can help patients and families navigate this challenging diagnosis.

When cancer reaches the protective layers of the nervous system

Treatment for metastases to the meninges focuses on controlling the spread of cancer cells, relieving symptoms, and maintaining quality of life for as long as possible. The leptomeninges, meaning the thin membranes that cover and protect the brain and spinal cord, along with the cerebrospinal fluid (CSF) that flows around these structures, become affected when cancer cells travel from their original location to this area. This condition is also called leptomeningeal metastases, leptomeningeal disease, neoplastic meningitis, or carcinomatous meningitis.^[2]

Treatment decisions depend heavily on several factors, including which type of cancer originally spread to the meninges, how advanced the disease is, the patient’s overall health status, and whether the systemic cancer elsewhere in the body is responding to treatment. Because this condition typically occurs in people who already have advanced cancer, doctors must balance aggressive treatment against preserving quality of life and managing side effects. The approach is highly individualized, and medical teams work closely with patients to determine the best path forward.^[12]

Healthcare providers have recognized that people with cancer are living longer than in the past, which means leptomeningeal metastases are being diagnosed more frequently. Approximately five to eight percent of patients with solid tumors and five to fifteen percent of those with blood cancers develop this complication. The most common cancers that spread to the meninges include breast cancer, lung cancer, melanoma, acute lymphocytic leukemia, and non-Hodgkin’s lymphoma.^[3][4]

Standard approaches to treating leptomeningeal metastases

The foundation of treatment for leptomeningeal metastases typically involves a combination of three main approaches: radiation therapy, chemotherapy delivered directly into the cerebrospinal fluid space, and systemic chemotherapy or targeted drugs. The entire nervous system requires treatment because cancer cells spread widely through the cerebrospinal fluid, settling in various locations throughout the brain and spinal cord.^[12]

Radiation therapy

Radiation therapy plays an important role in managing symptomatic areas and treating visible tumor deposits. Doctors use radiation to relieve symptoms at specific sites where the cancer is causing problems, such as the base of the skull when cranial nerves are affected, or along the spine when nerve roots are compressed. Radiation helps by reducing the size of tumor nodules on the meninges and relieving blockages in cerebrospinal fluid flow that can cause increased pressure in the brain.^[8]

A typical radiation treatment course delivers approximately 2400 rads (24 Gray) divided into eight sessions over ten to fourteen days, though dosing can range from 20 Gray over one week to 30 Gray over three to four weeks depending on the specific situation. For patients with leukemia or lymphoma affecting the meninges, the standard dose is usually 30 Gray given in ten sessions. The radiation oncologist carefully plans the treatment field to target the areas most affected while trying to minimize damage to the bone marrow, which could interfere with chemotherapy treatments.^[12]

Intrathecal chemotherapy

Intrathecal chemotherapy means delivering cancer-fighting drugs directly into the cerebrospinal fluid. This approach is necessary because many chemotherapy drugs given through a vein cannot cross the blood-brain barrier, a protective layer that normally keeps harmful substances out of the brain and spinal cord. By injecting medication directly into the CSF space, doctors can achieve higher drug concentrations where the cancer cells are located.^[10]

The procedure can be performed in two ways. The first method involves a lumbar puncture, also called a spinal tap, where a needle is inserted into the lower back to access the fluid space around the spinal cord. The second method uses a special device called an Ommaya reservoir, which is a small dome-shaped container surgically placed under the scalp with a tube that connects to the fluid-filled spaces inside the brain. The Ommaya reservoir allows repeated treatments without multiple spinal taps, which is more comfortable for patients who need ongoing therapy.^[10]

The most commonly used intrathecal chemotherapy drugs include methotrexate, cytarabine (sometimes in a long-acting liposomal form), and thiotepa. The choice of drug depends on the type of primary cancer. For example, methotrexate is often used for breast cancer and lymphoma, while cytarabine may be preferred for certain blood cancers. Recent research has shown that adding intrathecal liposomal cytarabine to systemic treatment improved progression-free survival in patients with breast cancer who had newly diagnosed leptomeningeal metastases.^[8]

Systemic chemotherapy and targeted drugs

Treating the systemic cancer throughout the rest of the body remains critically important, since most patients with leptomeningeal metastases ultimately die from cancer elsewhere in their body rather than from the brain involvement alone. Modern chemotherapy regimens, particularly those designed to penetrate the central nervous system better, have shown promise in extending survival.^[12]

For patients with lung cancer and leptomeningeal metastases, studies have found that systemic treatment regimens containing drugs like pemetrexed, bevacizumab, or tyrosine kinase inhibitors (medications that block specific proteins that help cancer cells grow) were associated with improved survival. The mean survival time was six months, and these treatments significantly decreased the risk of death compared to other approaches.^[12]

Targeted cancer drugs work by attacking specific molecular features of cancer cells. Several targeted agents have shown activity against leptomeningeal disease. For patients with breast cancer that tests positive for the HER2 protein, trastuzumab emtansine has been used. For certain types of lung cancer called adenocarcinoma, drugs like erlotinib or gefitinib, which target mutations in the EGFR gene, may be helpful. Another drug called ceritinib has been used for non-small cell lung cancer patients whose tumors have specific genetic changes.^[10]

Managing side effects and supportive care

Side effects from these treatments can be significant and require careful monitoring. Radiation to the brain can cause fatigue, hair loss in the treated area, skin irritation, and sometimes nausea. Longer-term effects may include changes in memory or thinking abilities. Intrathecal chemotherapy can cause headaches, nausea, fever, and sometimes inflammation of the meninges called chemical meningitis. There is also a risk of more serious complications like seizures or infection if the Ommaya reservoir becomes contaminated.^[12]

Doctors prescribe medications to control symptoms and side effects throughout treatment. These might include corticosteroids to reduce swelling around the brain and spinal cord, anti-seizure medications if needed, pain medications, and drugs to prevent nausea and vomiting. Some patients who are too ill to tolerate active cancer treatment receive only supportive care focused on comfort and symptom management.^[2]

Promising treatments being tested in clinical trials

Researchers are actively studying new ways to treat leptomeningeal metastases through clinical trials. These studies test innovative drugs and approaches that may offer better outcomes than current standard treatments. Clinical trials are conducted in phases, with Phase I focusing on safety and finding the right dose, Phase II examining whether the treatment works and continuing to monitor safety, and Phase III comparing the new treatment directly against the current standard of care.^[8]

Novel intrathecal agents

One area of active research involves developing new drugs that can be safely delivered directly into the cerebrospinal fluid. Scientists are evaluating the safety and effectiveness of intrathecal trastuzumab, the targeted antibody drug normally given intravenously for HER2-positive breast cancer. Early studies are assessing whether delivering this medication directly into the CSF can effectively reach cancer cells in the leptomeninges while maintaining an acceptable safety profile.^[8]

Advanced systemic therapies

Newer generations of targeted therapies and immunotherapies are showing promise for treating brain and leptomeningeal involvement from cancer. Immunotherapy works by helping the patient’s own immune system recognize and attack cancer cells. These treatments have already improved outcomes for patients with brain metastases, and researchers are now studying whether they can also help those with leptomeningeal disease.^[8]

For lung cancer patients, several newer tyrosine kinase inhibitors that better penetrate the blood-brain barrier are being tested. These drugs are designed to reach higher concentrations in the cerebrospinal fluid compared to older medications. Early results suggest these agents may control disease in the central nervous system for longer periods, potentially extending survival beyond what was previously possible.^[13]

Researchers are also investigating combinations of treatments. For example, some trials are testing whether combining targeted drugs with intrathecal chemotherapy works better than either approach alone. Other studies examine whether adding immunotherapy to standard treatments can improve outcomes. These combination approaches aim to attack the cancer through multiple mechanisms simultaneously.^[8]

Evaluating treatment response in trials

One challenge in studying leptomeningeal metastases is determining whether treatments are working. Researchers use three main methods to assess response: standardized neurological examinations to check whether symptoms are improving or worsening, analysis of cerebrospinal fluid to look for cancer cells using techniques like cytology (examining cells under a microscope) or flow cytometry (using lasers to identify cancer cells), and imaging studies like MRI scans to see if visible tumors are shrinking.^[12]

Disease progression is defined by worsening neurological examination findings directly related to the leptomeningeal metastases or worsening appearance on brain and spine imaging. Researchers report both how long patients live overall and how long they live without their disease getting worse, a measure called progression-free survival. In recent trials, treatment with newer agents has controlled cancer cells in the meninges for several months, and in some cases with targeted therapies, for more than a year for certain types of cancer.^[2][8]

Access to clinical trials

Clinical trials for leptomeningeal metastases are being conducted at major cancer centers in the United States, Europe, and other regions. Eligibility criteria vary by study but generally include having a confirmed diagnosis through imaging or cerebrospinal fluid analysis, adequate organ function to tolerate treatment, and reasonable overall health status. Some trials focus on specific types of primary cancer, such as breast cancer or lung cancer, while others accept patients with various solid tumors.^[6]

Patients interested in clinical trials should discuss options with their oncology team. Doctors can help determine which trials might be appropriate and assist with the enrollment process. While clinical trials offer access to cutting-edge treatments, they also involve additional monitoring and visits, and there is no guarantee the experimental treatment will work better than standard therapy. However, participating in research helps advance medical knowledge and may provide access to promising new approaches.^[6]

Most common treatment methods

• Radiation therapy
  • Focal radiation to symptomatic areas where cancer is causing specific problems
  • Treatment of visible tumor nodules on the meninges
  • Relief of cerebrospinal fluid blockages causing increased brain pressure
  • Typical doses range from 20 to 30 Gray delivered over one to four weeks
  • Particularly useful for treating cranial nerve involvement or spinal nerve compression
• Intrathecal chemotherapy
  • Methotrexate injected directly into cerebrospinal fluid for breast cancer and lymphoma
  • Cytarabine, including liposomal long-acting formulations, for blood cancers and some solid tumors
  • Thiotepa for certain types of primary cancers
  • Delivered via lumbar puncture or Ommaya reservoir surgically placed under the scalp
  • Allows higher drug concentrations to reach cancer cells in the meninges
• Systemic chemotherapy
  • Pemetrexed for lung cancer with better central nervous system penetration
  • Bevacizumab, a drug that blocks blood vessel formation to tumors
  • Various combination regimens chosen based on the primary cancer type
  • Important for treating systemic disease throughout the body
• Targeted therapy
  • Trastuzumab emtansine for HER2-positive breast cancer, both systemically and being studied intrathecally
  • Erlotinib and gefitinib for lung adenocarcinoma with EGFR mutations
  • Ceritinib for non-small cell lung cancer with ALK genetic changes
  • Newer generation tyrosine kinase inhibitors with better blood-brain barrier penetration
• Immunotherapy
  • Emerging role in managing leptomeningeal metastases being studied in clinical trials
  • Works by activating the patient’s immune system to recognize and attack cancer cells
  • Showing promise in brain metastases and being evaluated for leptomeningeal disease
• Supportive care
  • Corticosteroids to reduce swelling and inflammation around the brain and spinal cord
  • Anti-seizure medications when needed to prevent or control seizures
  • Pain management medications for headaches, back pain, and nerve pain
  • Anti-nausea drugs to control treatment side effects
  • Palliative care focused on comfort when active treatment is not appropriate